CAPR Stock Jumps As Analysts Hike Price Targets Ahead FDA Call

Capricor Therapeutics Inc. stocks have been trading up by 14.24 percent following upbeat sentiment on its lead therapy developments.

Live Update At 08:32:33 EDT: On Wednesday, September 30, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 14.24%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Capricor Therapeutics (CAPR) is trading like a classic event-driven biotech. Over the last few weeks, CAPR has chopped between roughly $8.3 and $9.5 on the daily chart, with recent closes slipping back toward the mid‑$8 range after testing above $9. This tells traders the stock is consolidating after a strong run but still holding prior gains.

Intraday, CAPR’s 5‑minute chart shows a big morning surge from around $10 to the low‑$12s before fading back toward $10–$11. That’s textbook volatility around news and shows active day trading flows. Range expansion like this can be a gift for disciplined short‑term traders who respect risk.

Fundamentally, CAPR is still a development‑stage biotech burning cash. The latest quarter shows a net loss of about $40.7M, negative operating cash flow of roughly $31.5M, and free cash flow around -$37.4M. Returns on equity and assets are deeply negative, which is normal for a company without commercial revenue yet.

More Breaking News

• CNTB Stock In Focus As Analysts Trim Targets After Mixed Asthma Data
• ITUB Stock Grinds Higher As Bank Metrics Draw Trader Focus
• CIFR Stock Pulls Back As Traders Weigh Heavy Losses And High Valuation
• NCI Stock Slides After Parabolic Spike, Volatility Draws Traders

On the plus side, Capricor Therapeutics reports a strong current ratio near 7.4 and over $200M in cash and short‑term investments, giving CAPR a solid liquidity runway. With price‑to‑book around 2.1, the market is already assigning premium value to its pipeline and upcoming deramiocel catalyst.

Why Traders Are Watching CAPR Into The FDA Decision

CAPR has suddenly moved onto many biotech watchlists because multiple big‑name firms are lining up behind the same core catalyst. B. Riley upgraded Capricor Therapeutics to Buy from Neutral, hiking its price target from $5 to $21. The firm points directly to the 2026/11/22 FDA action date for deramiocel and a possible data update at the World Muscle Society meeting on 2026/10/03 as key drivers.

Not long before that, Piper Sandler shifted CAPR to Overweight from Neutral and yanked its target up from $2 to $25. When two separate shops both see favorable risk/reward into the same binary event, traders pay attention. It means the Street is converging on a bullish read of the data and regulatory path, even though approval is never guaranteed in biotech.

The tape backs that up. Capricor Therapeutics shares jumped about 4–5% after each upgrade, with the stock reacting immediately to the new targets. That’s real money stepping in, not just chatter. CAPR’s intraday spikes toward $12 reflect momentum traders piling in on the headlines, then profit‑taking once the initial surge cools.

Zooming out, FactSet shows Capricor Therapeutics sitting at an Overweight consensus with a mean price target of $31.78, notably above both the $21 B. Riley and $25 Piper Sandler marks. That tells traders the broader analyst set sees even more upside if deramiocel hits. Add in a fresh Schedule 13G showing a significant passive stake in CAPR, and you have a picture of growing institutional confidence.

For active traders, CAPR is now an event play with defined dates, heavy volatility, and strong sentiment — the exact mix many in the small‑cap biotech niche look for.

Conclusion

Right now, Capricor Therapeutics is all about the countdown to 2026/11/22. CAPR’s deramiocel program is pulling in bullish calls from B. Riley and Piper Sandler, with price targets jumping from single digits to the low‑$20s and mid‑$20s. The stock has already rewarded momentum traders with 4–5% pops on upgrade days and fast intraday swings from $10 to the $12 area.

At the same time, the numbers remind everyone this is still a high‑risk biotech story. Capricor Therapeutics is running sizeable quarterly losses, burning tens of millions in cash, and relying on its balance‑sheet strength and capital market access to stay in the game. The Schedule 13G stake and Overweight consensus, including that $31.78 average target, signal that some larger players are comfortable with that trade‑off.

For short‑term traders, CAPR’s job is simple: treat this like a volatile catalyst stock, not a “marry it forever” name. The daily chart shows clear support and resistance zones, and the 5‑minute action proves liquidity is there for quick in‑and‑out strategies. This is exactly where clear, rules‑based planning matters — as Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.” — and CAPR’s current volatility demands that kind of conviction before hitting the buy or sell button.

As Tim Sykes loves to say, “Trade the ticker, not the story.” With CAPR, the story around deramiocel and the FDA is driving the action — but disciplined trading rules, risk management, and the ability to cut losses fast will decide who actually walks away with profits. This analysis is for educational and research purposes only, not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.